Syntaxin Ltd has appointed Laurence Barker to the newly created position of head of business development. Dr Barker was formerly associate director of business development at the Munich-based antibody company, MorphoSys AG.
Based in Oxford, UK, Syntaxin develops biologic drugs to control cell secretion.
In his new job, Dr Barker will be responsible for putting into effect plans for commercialising the company’s proprietary re-targeted endopeptidase discovery platform. Syntaxin’s products exploit the natural pharmacology of bacterial toxins.
In his previous position at MorphoSys, Dr Barker completed several licensing deals and strategic collaborations with US, European and Japanese companies, and led the team that negotiated MorphoSys’s 2007 partnership with Novartis.
Copyright 2008 Evernow Publishing Ltd